Tokyo, Aug. 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062551) titled 'Side effects and their management associated with DMD gene therapy: A study based on real-world clinical data in Japan' on Aug. 18.
Study Type:
Observational
Primary Sponsor:
Institute - National Center of Neurology and Psychiatry
Condition:
Condition - Duchenne Muscular Dystrophy (DMD)
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - This study aims to clarify the real-world profile of side effects following the administration of a novel gene therapy (delandistrogene moxeparvovec) for Duchenne Muscular Dystrophy (DMD). By retrospectively analyzing anonymized real...